4.09 Problems with the VISION Trial & Stool Transplant Plus Nivo for Metastatic Melanoma
07.23.2021 - By Plenary Session
Download our free app to listen on your phone
Today we have two short monologues for you on recent papers. The first, by popular request, is the problems with the VISION trial, which treated metastatic castration-resistant prostate cancer with lutetium-177–PSMA-617 (Lu-177–PSMA-617) radioligand therapy and standard of care. The second is on the paper recently published in Science titled "Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients".
Fecal transplant: doi.org/10.1126/science.abb5920
Back us on Patreon! www.patreon.com/plenarysession
Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew